Sweden-based medical technology provider RaySearch Laboratories has received approval from China Food and Drug Administration (CFDA) to market its treatment planning system, RayStation.
Built on the latest software architecture, the RayStation system integrates all the company’s advanced treatment planning solutions into a flexible treatment planning system.
The system, which features a graphical user interface, combines multi-criteria optimisation tools with full support for 4D adaptive radiation therapy.
It also includes RaySearch’s algorithms for intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) optimisation and accurate dose engines for photon, electron and proton therapy.
RaySearch CEO Johan Löf said that China is the fastest growing radiation therapy market and so this approval is of great strategic importance to the firm.
"Together with Kang Li Da, we have already been active on the Chinese market for more than a year and a half so we know there is a large interest for RayStation in China," Löf said
"We are very excited that we can now start offering RayStation to the Chinese clinics."
China-based Kang Li Da Trading has been distributing the company’s products in the country since November 2011.
Kang Li Da has been actively involved in pre-marketing activities and in securing regulatory clearance for the system. The firm will also sell and provide after sales service for RayStation in the country.
According to RaySearch, China is one of the world’s largest radiation therapy markets with approximately 1,300 radiation therapy clinics. In less than five years, this figure is expected to reach 2,000.